

SAFETY DATA SHEET

(Following Regulations (EC) No 1907/2006 & (EC) No 1272/2008)

SDS Number: RP211 Date of first issue: 11 April 2018 Date of last revision: 21 February 2022

1 - Identification of product

1.1 - Identification of Product

Tradenames: AL2100, AL2300, Alfibond 2100, Alfibond 2300, Alfipatch, I-Alfipatch,

These products contain Refractory Ceramic Fibres (RCF)/Alumino-silicate wools (ASW) ((RCF/ASW)). Index Number: 650-017-00-8 of Annex VI CAS number: 142844-00-6 CAS number: 142844-00-6 CAS Name: Refractories, fibres, aluminosilicate Registration number: 01-2119458050-50-0002

1.2 - Use of Product

Use of the products is restricted to professional users for application as thermal insulation, heat shields, heat containment, gaskets and expansion joints at temperatures up to 1400°C in industrial furnaces, ovens, kilns, boilers and other process equipment and in the aerospace and automotive industries. Products are not intended for direct sale to the general public

• Primary Use: Manufacture of fibre (this use refers to the initial production of the fibre and is therefore not relevant to the downstream user)

- Secondary Use: Conversion into wet and dry mixtures and articles (refer to section 8)
 Tertiary Use: Installation, removal (industrial and professional) / Maintenance and service life (industrial and professional) (refer to section 8)

Uses Advised Against Spraying of the product

1.3 - Identification of Company

IDENTIFICATION OF THE MANUFACTURER/SUPPLIER

Morgan Advanced Materials Thermal Ceramics 30-36 Birralee Road, Regency Park, SA 5010, Australia Telephone: 1800 467 858 Fax: 1800 467 850

Website

www.morganthermalceramics.com sds.tc@morganplc.com

1.4 - Emergency information

EMERGENCY CONTACT NUMBER

Tel 1: +91 (4172) 244 313 extn no. 215 or 201 Language: English

Opening hours: Only available during office hours

2 - Hazard Identification

2.1 - Classification of the substance/ mixture

2.1.1 Classification according to Regulation (EC) No 1272/2008

Under the Classification, Labelling and Packaging regulations (CLP) 1272/2008 EEC RCF/ASW has been classified as a 1B carcinogen.

2.1.2 Additional information:

The International Agency for Research on Cancer (IARC) reaffirmed in 2001 that group 2B ("possibly carcinogenic to humans") remains the appropriate classification for RCF/ASW. In accordance with 1st adaptation to Technical Progress of Regulation (EC) No 1272/2008 as published 10th August 2009, the classification as "irritant" has been removed for all types of manmade vitreous fibres (MMVFs).

2.2 - Labelling Elements

Component	Classification	Hazard pictogram & Symbol	H Statement
Refractory Ceramic Fibres (Alumino-silicate wools)	(EC)No. 1272/2008.	GHS 08	H350I

Hazard pictogram	GHS 08	
Signal Word	Danger	
Hazard Statements	May cause cancer by inhalation (H350i)	
Precautionary statements	Do not handle until all safety instructions have been read and understood. (P202)	
	Use personal protective equipment as required. (P281)	

2.3 - Other hazards which do not result in classification

Mild mechanical irritation to skin, eyes and upper respiratory system may result from exposure. These effects are usually temporary

3 - Composition / Information On Ingredients

These products in the form of boards (pre-sized or not), shapes and cartons, are made of refractory ceramic fibres

Component	CAS No.	% w/w	Classification
Refractories, Fibres, Aluminosilicate	142844-00-6	Up to 95	Non-hazardous
Colloidal Alumina, Alumina	1344-28-1	Up to 65	Non-hazardous
Barium Sulfate*	7727-43-7	Up to 20	Non-hazardous
Silica Amorphous** **Applies to Alfibond 2100 and Alfibond	7631-86-9	Up to 33	Non-hazardous

Composition:

CAS definition: Chemical composition of Refractory Ceramic Fibres (RCF/ASW): SiO2: 45-60 %, Al2O3: 28-55 %, ZrO2 < 18%

None of the components are radioactive under the terms of European Directive Euratom 96/29.

4 - First-Aid measures

Skin

Handling of this material may generate mild mechanical temporary skin irritation. If this occurs, rinse affected areas with water and wash gently. Do not rub or scratch exposed skin.

Eyes

In case of eye contact flush abundantly with water; have eye bath available. Do not rub eyes. Seek medical attention is irritation persists.

Nose and Throat

If these become irritated move to a dust free area, drink water and blow nose. Seek medical attention if irritation persists.

If symptoms persist, seek medical advice.

4.2 - Most Important symptoms and effects, both acute and delayed

No symptoms or effects expected either acute or delayed

4.3 - Indication of any immediate medical attention and special treatment required

No special treatment required, if exposure occurs wash exposed areas to avoid irritation.

5 - Fire-fighting measures

5.1 - Extinguishing media

Use extinguishing agent suitable for surrounding combustible materials.

5.2 - Special hazards arising from the substance or mixture

Non-combustible products,

5.3 - Advice for firefighters

Packaging and surrounding materials may be combustible.

6 - Accidental Release Measures

6.1 - Personal precautions, protective equipment and emergency procedures

Where abnormally high dust concentrations occur, provide workers with appropriate protective equipment as detailed in section 8.

Restrict access to the area to a minimum number of workers required. Restore the situation to normal as quickly as possible.

6.2 - Environmental precautions

Prevent further dust dispersion for example by damping the materials. Do not flush spillage to drain and prevent from entering natural watercourses. Check for local regulations, which may apply

6.3 - Methods and materials for containment and clean up

Pick up large pieces and use a vacuum cleaner fitted with a high efficiency filter (HEPA) If brushes are used, ensure that the area is wetted down first. Do not use compressed air for clean up. Do not allow to become windblown.

6.4 - Reference to other sections

For further information, please refer to sections 7 and 8

7 - Handling and storage

7.1 - Precautions for safe handling

Handling can be a source of dust emission and therefore the processes should be designed to limit the amount of handling. Whenever possible, handling should be carried out under controlled conditions (i.e., using dust exhaust system). Regular good housekeeping will minimise secondary dust dispersal.

7.2 - Conditions for safe storage

Store in original packaging in a dry area. Always use sealed and clearly labelled containers. Avoid damaging containers. Reduce dust emission during unpacking. Emptied containers, which may contain debris, should be cleaned before disposal or recycling. Recyclable cardboard and/or plastic films are recommended for packaging.

7.3 - Specific end use

The main application of these products is as thermal insulation. Use of the products is restricted to professional users. Please refer to section 8 and the relevant exposure scenario

8 - Risk Management Measures / Exposures Controls / Personal Protection

8.1 - Control parameters

Industrial hygiene standards and occupational exposure limits vary between countries and local jurisdictions. Check which exposure levels apply to your facility and comply with local regulations. If no regulatory dust or other standards apply, a qualified industrial hygienist can assist with a specific workplace evaluation including recommendations for respiratory protection. Examples of national OELs (November 2014) are given in the table below.

COUNTRY	Total Dust (mg/m ³)	Resp Dust (mg/m ³)	RCF (fibre/ml)	Source
EU BOELV			0.3	Carcinogens and Mutagens Directive (DIRECTIVE 2004/37/EC)
Austria	10	6	0.3	Grenzwerteverordnung
Belgium	10	3	0.3	Valeurs limites d'exposition professionnelle – VLEP/ Grenswaarden voor beroepsmatige blootstelling – GWBB
Denmark	10	5	0.3	Grænseværdier for stoffer og materialer
Finland	No limit	No limit	0.2	Finnish Ministry of Social Affairs and Health
France	10	5	0.1	Institut National de Recherche et de Sécurité
Germany	10	1.25	0.2*	TRGS 900
Hungary	No limit	No limit	0.3	EüM-SZCSM rendelet
Ireland	10	4	0.3	HAS – Ireland
Italy	10	3	0.3	Decree 44/20
Luxembourg	10	6	0.3	Agents Chimiques, Cancérigènes Ou Mutagènes Au Travail
Netherlands	10	5	0.3	SER
Norway	10	5	0.1	Veiledning om administrative normer for forurensning i arbeidsatmosfære
Poland	No limit	No limit	0.3	Dziennik Ustaw 2010
Spain	10	3	0.3	INSHT
Sweden	10	5	0.2	AFS 2005:17
Switzerland	10	6	0.25	SUVA - Valeurs limites d'exposition aux postes de travail
UK	10	4	0.3	EH40/2020

8.1.1 DNEL/DMEL (DERIVED NO-EFFECT LEVEL/DERIVED MINIMAL EFFECT LEVEL)

SCOEL (Scientific Committee on Occupational Exposure Limits) published a report in 2012 using all available data to set an OEL for RCF, because this substance is a fibre and its hazard is related to inhalation, this OEL is more appropriate than a modelled DNEL. The report concludes as follows:

Assuming a 45 years exposure the average cumulative exposures of 147.9 and 184.8 fmo/ml, respectively, result in an average fibre concentrations of 0.27 and 0.34 f/ml. Considering these values as no observed adverse effect levels SCOEL proposes an OEL of 0.3 f/ml.

Information on monitoring procedures

United Kingdom

MDHS 59 specific for MMVF: "Man-made mineral fibre - Airborne number concentration by phase-contrast light microscopy" and MDHS 14/4 "General methods for sampling and gravimetric analysis of respirable and inhalable dust"

NIOSH

NIOSH 0500 "Particulates not otherwise regulate, total" NIOSH 0600 "Particulates not otherwise regulate, respirable" NIOSH 7400 "Asbestos and other fibres by PCM"

8.2 - Exposure controls

8.2.1 APPROPRIATE ENGINEERING CONTROLS Review your application(s) and assess situations with the potential for dust release. Where practical, enclose dust sources and provide dust extraction at source. Designate work areas and restrict access to informed and trained workers. Use operating procedures that will limit dust production and exposure of workers. Keep the workplace clean. Use a vacuum cleaner fitted with a HEPA filter; avoid using brooms and never use compressed air for clean up.

If necessary, consult an industrial hygienist to design workplace controls and practices. The use of products specially tailored to your application(s) will help to control dust. Some products can be delivered ready for use to avoid further cutting or machining. Some could be pretreated or packaged to minimise or avoid dust release during handling. Consult your supplier for further details

Table of Uses and Risk Management Measures (RMM):

Intended use RMM - Hierarchy of Controls

 Where it is practical to do so, automatically feed RCF/ASW in to the process Where practical to do so, segregate dry and wet processing Enclose the process where practically possible. Where practical to do so, segregate machine areas and restrict access to operators involved in the process. Enclose Machines as far as practically possible. Install LEV where possible, when machine finishing, handling, compressing and hand cutting to remove dust at source Employ experienced personnel – trained in the correct use of fibrous products PPE and RPE used for all dusty tasks Provide vacuum cleaner connection point to central system where practical or use a portable HEPA vacuum Regular clean up – using a wet scrubbing unit where practically possible and in general a HEPA vacuum should be used. Dry brushing and use of compressed air should be prohibited Waste materials to be contained at source, labelled and stored separately for disposal or recycling.
RMM - Hierarchy of Controls
 Use pre-cut, pre-sized pieces where practically possible. Allow access only to trained (authorised) operators Where practically possible, perform all hand cutting in a segregated area, on a down draft bench. Clean up work area regularly during the shift using a HEPA equipped vacuum cleaner. Prohibit use of dry brushing and compressed air cleaning. Bag and seal waste immediately at source. Use PPE and RPE appropriate to task. Employ good hygiene practices.
RMM - Hierarchy of Controls
 Where practically possible enclose or segregate the work area. Allow only authorised personnel.

8.2.2 - Personal Protective Equipment

Skin Protection

Wear industrial leather gloves and work clothes, which are loose fitting at the neck and wrists. Solied clothes should be cleaned to remove excess dust before being taken off (e.g. use vacuum cleaner, not compressed air). Each worker should be provided with two lockers in an appropriate changing and washing area. It is good hygiene practice to ensure work clothes are washed separately by the employer. Work clothes should not be taken home.

Eye Protection

As necessary, wear goggles or safety glasses with side shields

Respiratory Protection

For dust concentrations below the applicable exposure limit value, RPE is not required but FFP2 respirators should be provided for use on a voluntary basis. For short term operations where excursions are less than ten times the applicable limit value, use FFP3 respirators. In case of higher concentrations or where the concentration is not known, please seek advice from your company and/or your supplier. You may also refer to the ECFIA code of practice available on the ECFIA's web site: www.ecfia.eu

Information and Training of workers

This should include:

- The applications involving RCF/ASW-containing products;
- The potential risk to health resulting from the exposure to fibrous dust;
- The requirements regarding smoking, eating and drinking at the workplace; The requirements for protective equipment and clothing;
- The good working practices to limit dust release;
- The proper use of protective equipment.

8.2.3 - Environmental Exposure Controls

RCF/ASW is inorganic, inert and stable and it is not soluble in water (solubility <1mg/litre) and as such does not pose a detrimental effect on the environment.

Processes involving the manufacturing or use of RCF/ASW should be filtered to minimise fibre emissions to air Waste RCF/ASW should be stored in closed containers and placed in to deep landfills, giving therefore little opportunity for release. General good practice for spills and waste is to prevent products from being windblown, by covering and damping the waste materials. Contain spillages to prevent access to drain.

Refer to local, national or European applicable environmental standards for release to air water and soil. For waste, refer to section13

9 - Physical and chemical properties

Information on basic physical and chemical properties State Colour Odour Odour threshold рΗ Melting point/freezing point Initial boiling point and boiling point range Flash point Evaporation rate . Flammability (solid, gas) Upper/lower flammability or explosive limits Vapour pressure Vapour density **Relative density** Solubility(ies) Partition co-efficient: n-octanol/water Auto-ignition temperature **Decomposition temperature** Viscosity Other safety information Particle Characteristics Explosive properties **Oxidising properties** 10 - Stability and Reactivity

Not applicable White or coloured board/shape White None Not Applicable Not applicable > 1750°C Not applicable 2.50 - 2.75 Kg/m³ Not soluble in water Not applicable Not applicable

10.1 - Reactivity

RCF/ASW is stable and non reactive.

10.2 - Chemical Stability

RCF/ASW is inorganic, stable and inert

10.3 - Possibility of Hazardous Reactions

None

10.4 - Conditions to Avoid

Please refer to handling and storage advice in Section 7

10.5 - Incompatible Materials

None

10.6 - Hazardous decomposition products

Upon heating above 900°C for sustained periods, this amorphous material begins to transform to mixtures of crystalline phases. For further information please refer to Section 16.

11 - Toxicological information

Toxicokinetics, metabolism and distribution

11.1.1 Basic toxicokinetics Exposure is predominantly by inhalation or ingestion. Man made vitreous fibres of a similar size to RCF/ASW have not been shown to migrate from the lung and/or gut and do not become located in other organs of the body

11.1.2 Human Toxicological data

In order to determine possible human health effects following RCF exposure, the University of Cincinnati has been conducting medical surveillance studies on RCF workers in the U.S.A. The Institute of Occupational Medicine (IOM) has conducted medical surveillance studies on RCF workers in European manufacturing facilities.

Pulmonary morbidity studies among production workers in Europe and U.S.A. have demonstrated an absence of interstitial fibrosis. In the European study a reduction of lung capacity among smokers has been identified, however, based on the latest results in the U.S.A. study this reduction is no longer statistically significant.

A statistically significant correlation between pleural plaques and cumulative RCF exposure was evidenced in the USA longitudinal study.

The U.S.A. mortality study did not show evidence of increased lung tumour development either in the lung parenchyma or in the pleura.

11.1 - Information on hazard classes as defined in Regulation (EC) No 1272/2008

· Acute toxicity: short term inhalation

No data available: Short term tests have been undertaken to determine fibre (bio) solubility rather than toxicity; repeat dose inhalation tests have been undertaken to determine chronic toxicity and carcinogenicity.

Acute toxicity: oral No data available: Repeated dose studies have been carried out using gavage. No effect was found.

 Skin corrosion/irritation: Not a chemical irritant according to test method OECD no. 404

 Serious eye damage/irritation: Not possible to obtain acute toxicity information due to the morphology and chemical inertness of the substance

· Respiratory or skin sensitisation No evidence from human epidemiological studies of any respiratory or skin sensitisation potential

Germ cell mutagenicity; Method: In vitro micronucleus test Species: Hamster (CHO) Dose: 1-35 mg/ml o Routes of administration: In suspension o Results: Negative

 Carcinogenicity; Method: Inhalation. Multi-dose Species: Rat, Dose: 3 mg/m3,9 mg/m3 and 16 mg/m3

Routes of administration: Nose only inhalation Results: Fibrosis just reached significant levels at 16 and 9 mg/m3 but not at 3 mg/m3. None of the parenchymal tumour incidences were higher than the historical control values for this strain of animal.

Method: Inhalation. Single dose Species: Rat Dose: 30 ma/m3 Routes of administration: Nose only inhalation Results: Rats were exposed to a single concentration of 200 WHO fibres/ml specially prepared RCF for 24 months. High incidence of exposure-related pulmonary neoplasms (bronchoalveolar adenomas and carcinomas) were observed. A small number of mesotheliomas were observed in each of the fibre exposure groups (Mast et al 1995a). Method: Inhalation. Single dose Species: Hamster

Dose: 30 mg/m3

Routes of administration: Nose only inhalation

Results: Hamsters were exposed to a single concentration of 260 WHO fibres/ml specially prepared RCF for 18 months and developed lung fibrosis, a significant number of pleural mesotheliomas (42/102) but no primary lung tumours (McConnell et al 1995).

Method: Inhalation. Single dose Species: Rat Dose: RCF1: 130 F/ml and 50 mg/m3 (25% of non fibrous particles) RCF1a: 125 F/ml and 26 mg/m3 (2% of non fibrous particles)

Routes of administration: Nose only inhalation Results: Rats were exposed to RCF1 and RCF1a for 3 weeks. The objective of the study was to compare lung retention and biological effects of the original RCF1 compared to RCF1a. The main difference of these 2 samples was the non fibrous particle content of respectively 25% versus 2%. The post treatment observation was 12 months. Alveolar clearance was barely retarded after RCF1A exposure. After RCF1 exposure , however, a severe retardation of clearance was observed. (Bellmann et al 2001) (Source: publication)

After intraperitoneal injection of ceramic fibres into rats in three experiments (Smith et al 1987, Pott et al 1987, Davis et al 1984), mesotheliomas were found in the abdominal cavity in two studies, while the third report (Pott et al 1987) had incomplete histopathology. Only a few mesotheliomas were found in the abdominal cavity of hamsters after intraperitoneal injection in one experiment (Smith et al 1987). However, the ceramic fibres tested were of relatively large diameter. When rats and hamsters were exposed via intraperitoneal injection, tumour incidence was related to fibre length and dose (Smith et al 1987, Pott et al 1987, Miller et al 1999, Pott et al 1989). (From SCOEL publication (EU Scientific Committee on Occupational Exposure Limits) publication SCOEL/SUM/165, October 2010)

 Reproductive toxicity; Method: Gavage Species: Rat Dose: 250mg/kg/day Routes of administration: Oral

Results: No effects were seen in an OECD 421 screening study. There are no reports of any reproductive toxic effects of mineral fibres. Exposure to these fibres is via inhalation and effects seen are in the lung. Clearance of fibres is via the gut and the faeces, so exposure of the reproductive organs is extremely unlikely.

· STOT-Single exposure: Not applicable

- · STOT-Repeated exposure: Not applicable
- Aspiration hazard: Not applicable

Experimental studies for other components

(a) acute toxicity; not tested

(b) skin corrosion/irritation; no adverse effects

(c) serious eye damage/irritation; not tested

(d) respiratory or skin sensitisation: no adverse effects

(e) germ cell mutagenicity; no adverse effects

(f) carcinogenicity; no adverse effects

(g) reproductive toxicity; no adverse effects

(h) STOT-single exposure; not tested

(i) STOT-repeated exposure; no adverse effects

(j) aspiration hazard. not applicable

Negative results have been obtained in animal studies (EU method B 4) for skin irritation. Inhalation exposures using the nose only route produce simultaneous heavy exposures to the eyes, but no reports of excess eye irritation exist. Animals exposed by inhalation similarly show no evidence of respiratory tract irritation. Human data confirm that only mechanical irritation, resulting in itching, occurs in humans, Screening at manufacturers' plants in the UK has failed to show any human cases of skin conditions related to fibre exposure.

12 - Ecological information

12.1 - Toxicity

These products are insoluble materials that remain stable overtime and are chemically identical to inorganic compounds found in the soil and sediment; they remain inert in the natural environment.

No adverse effects of this material on the environment are anticipated.

12.2 - Persistence and degradability

Not established

12.3 - Bioaccumulative potential

Not established

12.4 - Mobility in soil

No information available

12.5 - Results of PBT and vPvB assessment

This mixture contains no substance considered to be persistent, bioaccumulating nor toxic (PBT).

This mixture contains no substance considered to be very persistent and very bioaccumulative (vPvB).

12.6 - Endocrine Disrupting Properties

No additional information available

12.7 - Other adverse effects

13 - Disposal Considerations

- 13.1 Disposal Considerations
- 14 Transport information
- 14.1 Transport information
- 15 Regulatory information
- 15.1 Regulatory information

16 - Other Information

16.1 - ADDITIONAL INFORMATION AND PRECAUTIONS TO BE CONSIDERED UPON REMOVAL OF AFTER SERVICE MATERIAL

16.2 - uses advised against

16.3 - NOTE

This Safety Data Sheet was originally produced in English and has subsequently been translated in to other languages; whilst every effort has been made to make this an accurate translation, please be aware that technical terms do not always translate correctly. The English version should always be considered as the reference version.

16.4 - Further Information

FURTHER INFORMATION Further information can be found on http://www.morganthermalceramics.com/ http://www.scfia.eu/ http://www.safeworkaustralia.gov.au/sites/swa/about/publications/pages/workplace-exposure-standards-airborne-contaminants

16.5 - Technical Datasheets

16.6 - Revision Summary

Content checked and revision date updated

16.7 - NOTICE

The information presented herein is based on data considered to be accurate as of the date of preparation of this Safety Data Sheet. However, no warranty or representation, express or implied, is made as to the accuracy or completeness of the foregoing data and safety information, nor is any authorization given or implied to practice any patented invention without a license. In addition, no responsibility can be assumed by the vendor for any damage or injury resulting from abnormal use, from any failure to adhere to recommended practices, or from any hazards inherent in the nature of the product.